Aptevo Therapeutics (APVO)
(Real Time Quote from BATS)
$0.19 USD
+0.01 (7.96%)
Updated Sep 20, 2024 10:48 AM ET
2-Buy of 5 2
D Value C Growth A Momentum C VGM
Balance Sheet
Fiscal Year End for Aptevo Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 17 | 23 | 46 | 43 | 12 |
Receivables | 0 | 3 | 4 | 2 | 7 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 6 |
Other Current Assets | 2 | 2 | 3 | 2 | 4 |
Total Current Assets | 19 | 27 | 53 | 47 | 30 |
Net Property & Equipment | 1 | 1 | 2 | 3 | 4 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 4 |
Deposits & Other Assets | 0 | 0 | 0 | 1 | 11 |
Total Assets | 25 | 34 | 57 | 54 | 53 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 4 | 3 | 6 | 13 |
Current Portion Long-Term Debt | 0 | 2 | 12 | 5 | 20 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 2 | 2 | 3 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 18 | 1 | 2 |
Total Current Liabilities | 7 | 9 | 35 | 15 | 38 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 1 | 4 | 20 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 16 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 13 | 16 | 55 | 37 | 42 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 236 | 224 | 215 | 202 | 180 |
Retained Earnings | -223 | -206 | -214 | -186 | -168 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 12 | 18 | 1 | 17 | 12 |
Total Liabilities & Shareholder's Equity | 25 | 34 | 57 | 54 | 53 |
Total Common Equity | 12 | 18 | 1 | 17 | 12 |
Shares Outstanding | 0.40 | 0.10 | 0.10 | 0.10 | 0.00 |
Book Value Per Share | 30.55 | 179.70 | 12.20 | 165.90 | 11.84 |
Fiscal Year End for Aptevo Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 8 | 10 | 17 | 19 | 21 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 2 | 2 | 2 | 2 |
Total Current Assets | 10 | 12 | 19 | 21 | 23 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 15 | 18 | 25 | 27 | 29 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 4 | 4 | 4 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 2 | 2 | 2 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 1 | 1 | 1 |
Total Current Liabilities | 5 | 6 | 7 | 7 | 7 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 10 | 12 | 13 | 12 | 13 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 241 | 236 | 236 | 232 | 227 |
Retained Earnings | -236 | -230 | -223 | -218 | -211 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 4 | 6 | 12 | 15 | 16 |
Total Liabilities & Shareholder's Equity | 15 | 18 | 25 | 27 | 29 |
Total Common Equity | 4 | 6 | 12 | 15 | 16 |
Shares Outstanding | 4.00 | 0.60 | 0.40 | 0.30 | 0.10 |
Book Value Per Share | 1.12 | 10.17 | 30.55 | 49.07 | 162.50 |